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A crucial pathogenetic role of serum amyloid A (SAA) in granulomatous inflammation of
sarcoidosis has recently been reported. In this study we analyzed SAA expression in detail,
starting from proteomic analysis of serum of sarcoidosis patients. We also used the faster ELISA
method that enabled us to examine a greater number of samples. Serum concentrations of SAA
were significantly higher in sarcoidosis patients than controls (p < 0.001), inversely correlated
with FEV1 and significantly higher in patients with subacute onset requiring prolonged and
multiple steroid treatments (class 6 SCAC) than in patients with subacute onset not requiring
therapy (class 4 SCAC) (p < 0.001). Our results suggest that serum amyloid A could be a suitable
marker of sarcoidosis: its serum concentrations are significantly higher in sarcoidosis patients
than controls, the protein is only expressed in gels of sarcoidosis patients and not in healthy
subjects, and the SAA1 isoforms could match the unidentified biomarker of sarcoidosis re-
ported in a previous proteomic study by another group. The effectiveness of SAA as a clinical
biomarker of sarcoidosis should now be investigated in a large prospective study.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Sarcoidosis is a systemic inflammatory granulomatous lung
disease with unknown etiology. Its clinical course is
unpredictable: spontaneous remission is reported in aboutlavage; ILD, interstitial lung
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to the study.
1 Elsevier Ltd. All rights reserved50% of cases, while 10e30% of patients develop a chronic
disorder with respiratory impairment.1e4 The most widely
studied biomarkers of the disease include: angiotensin
converting enzyme (ACE), soluble interleukin-2 receptor
(sIL-2R), chitotriosidase, lysozyme, neopterin, and other
cytokines and chemokines.5e10 However, no single
biomarker has sufficient sensitivity and specificity to be
recommended for clinical use.
The proteomic approach applied to the study of bron-
choalveolar lavage (BAL) and serum of sarcoidosis patients
revealed a protein pattern different to those of other inter-
stitial lung diseases and healthy controls, indicating some.
776 E. Bargagli et al.proteins of interest as potential biomarkers.11e16 At the
beginning of our studies on proteomics we compared BAL and
serum protein profiles in interstitial lung diseases11,12 and we
found increased expression of certain acute phase proteins,
especially serum amyloid A, in serum of sarcoidosis.14
Serum amyloid A (SAA) is an acute phase protein
released by the liver and the most abundant of its six iso-
types is SAA1.17 Its production is stimulated by IL1 and IL6.
Serum amyloid A is an acute phase reactant that transiently
binds high-density lipoproteins during inflammatory
responses.17 It may displace apo A-I, causing increased
catabolism of high-density lipoproteins, or inhibit lec-
ithinecholesterol acyltransferase activity, leading to low
levels of esterified serum cholesterol.18,19 Serum amyloid A
plays a variety of immunoinflammatory functions: it
induces chemotaxis and adhesion molecule expression, it
up-regulates metalloproteinases (in particular matrix-met-
alloproteinase-9 over-expressed in IPF and involved in lung
fibrotic remodeling) and it regulates apolipoprotein
metabolism.17 There is great interest in SAA in sarcoidosis
and the protein was recently proposed as a key regulator of
granulomatous inflammation in this disease.20 It induces
production of several cytokines and regulates Th-1 immune
responses through interaction with Toll-like receptor-220
but only a limited number of studies have considered its
potential as a biomarker of disease severity.
SAA concentrations have been detected in serum of
sarcoidosis patients together with other inflammatory and
acute phase proteins (including C-reactive protein, sIL-2r
and ACE). SAA levels proved significantly higher in
sarcoidosis patients than controls,10 particularly those with
associated anomalies of lipid metabolism.18
Our interest in SAA1 sprang from our proteomic analysis
(two-dimensional electrophoresis) of sarcoidosis
patients.14,21 Serum samples showed one or two spots of
SAA, which were never found in gels of control serum. This
prompted us to do detailed analysis of SAA1, also using the
faster ELISA method in order to handle a greater number of
samples.
Aims of the present study were: 1) to identify SAA1 by
a proteomic approach in serum of patients with sarcoidosis
and controls, 2) to determine concentrations of SAA1 by
ELISA 3) to further investigate SAA patterns in serum of
sarcoidosis patients.
Patients and methods
Subjects
Proteomic analysis of SAA was performed in serum of seven
sarcoidosis patients and seven controls. Serum concentra-
tions of SAA detected by ELISA were evaluated in 48
sarcoidosis patients and 17 controls. Sarcoidosis was diag-
nosed according to ATS/ERS/WASOG international
criteria.22 Detailed medical history, including professional
exposure, smoking history and pharmacological history, was
obtained at onset. All patients underwent lung function
tests including single-breath carbon monoxide diffusion
capacity according to ATS/ERS guidelines and reference
standards.23 Chest X-rays in posterioreanterior and lateral
projections were performed and radiological staging wasdone by an experienced radiologist according to widely
accepted criteria.24
Serum samples were obtained at the time of bronchos-
copy. The patients were consecutive cases of sarcoidosis
not on therapy (immunosuppressants or steroids) when
serum samples were drawn and bronchoalveolar lavage
carried out. The patients had been observed at the
Sarcoidosis Regional Referral Centre (Siena) for at least 3
years. Bronchoalveolar lavage was performed for diagnostic
and clinical purposes with informed consent of patients.
Briefly, the first sample was kept separate from the others
and was not used for immunological tests. Cells were
separated by centrifuge and the fluid fraction was frozen
for enzyme assays. Cell differential counts were per-
formed. Lymphocyte phenotype was analyzed by flow
cytometry (Facs-Calibur Becton & Dickinson) using anti-
CD3, CD4 and CD8 monoclonal antibodies (Becton & Dick-
inson). Serum ACE concentrations, BAL differential cell
count and BAL lymphocyte phenotype were also deter-
mined in all patients.
Patients included in the study were all sarcoidosis
patients with subacute onset of the disease. Patients with
acute Lo¨fgren’s syndrome (bihilar lymphadenopathy,
erythema nodosum and arthritis) were excluded. Our
population of patients was divided according to pheno-
type activity score SCAC.25 They were assigned to one of
three groups (corresponding to SCAC classes 4e6)
according to their need for treatment with steroids after
SAA1 assessment. One group consisted of 15 patients with
subacute onset and no need for systemic steroid therapy
(class 4 SCAC). Another group consisted of 17 sarcoidosis
patients with subacute onset requiring one period of
immunosuppressive treatment of 12 months or less, at
onset or in the follow-up period (class 5 SCAC). The last
group consisted of 16 patients with subacute onset
who needed several periods of immunosuppressive treat-
ment or long lasting treatment (more than 1 year) (class 6
SCAC).
Controls were all Caucasians with no history of asthma
or allergy and were not on any type of therapy. They had
been observed for 12 months without developing any
disease. Their lung function parameters were within
normal limits and bronchoscopy did not reveal any alter-
ations. Patients and controls gave their written informed
consent to the study, which was approved by the Local
Ethics Committee.Two-dimensional electrophoresis
Two-dimensional electrophoresis (2-DE) was performed as
previously described.26 The first dimension was run on
a nonlinear wide-range immobilized pH gradient IPG (pH
3.5e10, 18 cm IPG strips; Amersham Biosciences, Uppsala,
Sweden). The second dimension was run on 9e16% poly-
acrylamide linear gradient gels subsequently stained with
ammoniacal silver nitrate. Electrophoretogram images
were obtained with a computing densitometer (Molecular
Dynamics 300S; Sunnyvale, CA, USA) and processed with the
program Melanie. Spots were identified by gel matching
with reference gels in a 2-D database (SWISS-2D PAGE) and
by western blot, as previously reported.27
Table 2 Lung function parameters, radiological stages
and BAL findings in sarcoidosis patients and controls.
Controls Sarcoidosis p < 0.05
FEV1, % predicted 98.6  20.5 96.3  18.5 No
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Serum amyloid A concentrations were determined by
a commercial quantitative sandwich immunoassay modi-
fied by us (ANOGEN, Canada). Serum samples of patients
and controls were placed in appropriate microtiter wells,
pre-coated with a monoclonal antibody specific for SAA,
and incubated. SAA was bound and immobilized by the
antibody pre-coated in the wells. To quantify SAA in the
sample, the wells were washed and a standard prepara-
tion of horseradish peroxidase (HRP)-conjugated poly-
clonal antibody specific for SAA was added to each well to
“sandwich” the SAA immobilized in the first incubation.
The microtiter plate was incubated a second time. The
wells were thoroughly washed to remove all unbound HRP-
conjugated antibodies and TMB substrate solution was
allowed to react over a short incubation period. The wells
containing SAA and enzymeesubstrate reaction changed
color. The enzymeesubstrate reaction was terminated by
addition of sulphuric acid solution and the color change
was measured spectrophotometrically at 450 nm. Serum
concentrations of SAA were expressed in mg/ml.
Statistical analysis
Data was expressed as mean  standard deviation (M  SD).
Comparisons between groups were performed with the Man-
neWhitney non-parametric U test (p < 0.05). The different
variables were cross-correlated using the Spearman R coef-
ficient of correlation (p < 0.05). Statistical analysis was per-
formed using Stat Soft 7.0 software (Statistical 7.0 Stat Soft,
Inc, 1984e2004, Tulsa, USA) and graphic representation of
data was done with GraphPad Prism Version 4.0 software for
Windows (GraphPad Software 4, Inc., 1992e2004, La Jolla,
USA).
Results
Two-dimensional electrophoresis analysis of SAA was per-
formed in serum of seven sarcoidosis patients (3 male, mean
age 48.1  22.79 years; M  SD) and seven controls (4 male,
mean age 44.6  13.5). Serum concentrations of SAA (ELISA)
were evaluated in 48 sarcoidosis patients (15 male, mean age
53  19.1 years) and 17 controls (6 male; 49.5  12.4 years).
Table 1 shows the clinical characteristics of sarcoidosisTable 1 Personal data of sarcoidosis patients and
controls.
Sarcoidosis Controls
Subjects 48 17
Ages (M  SD) 53  19.1 49.5  12.4
Sex (M/F) 15/33 6/11
Race
Caucasian 46 17
African 2 0
Smokers (%)
Current 20.8 20
Ex 20.8 0
Never 58.3 80patients and controls. Lung function parameters (including
DLCO), radiological stages and BAL findings of sarcoidosis
patients are reported together with functional and immu-
nological parameters of healthy controls in Table 2. Globally
sarcoidosis patients had normal lung function test parame-
ters and elevated BAL lymphocyte count and CD4/CD8 ratio
(Table 2).
Two-dimensional electrophoresis analysis
Two-dimensional electrophoresis analysis of SAA in serum of
our sarcoidosis patients revealed that the protein resolved
into two spots with isoelectric point/molecular weights of
5.69/11000 kDa (spot A) and 6.15/11000 kDa (spot B). These
values are in line with those predicted for the primary gene
product and the des-Arg modification of the SAA1-alpha
locus. In 2-D gels, serum amyloid A1 was identified by
matching with a reference gel from SWISS-2D PAGE and
confirmed by immunoblot that revealed these two isoforms
of the protein. The isoforms of SAA1 in the gel of a sarcoidosis
patient are shown in Fig. 1. Relative volumes of spots A and B
in serumof sarcoidosis patients and controls were calculated
andexpressedaspercentage volumes. SAA1 spotswerenever
observed in silver stained gels of serum of controls, whereas
in sarcoidosis patients themean percentage volumes of spots
A and B were 0.05  0.07 %vol (M  SD) and 0.06  0.08 %vol
(M  SD), respectively (Table 3). Interestingly, the highest
percentage volumes of spots A and B were observed in two
patients with active sarcoidosis experiencing a flare-up of
respiratory symptoms accompanied by rapid deterioration of
radiological and functional parameters. These patients also
had ocular and cutaneous extrapulmonary localizations.
They both required prolonged and repeated treatment with
steroids.
ELISA assay
Serum concentrations of SAA analyzed by ELISA were signif-
icantly higher in sarcoidosis patients (4.07  1.32 mg/ml)FVC, % predicted 99.5  10.2 98  16.6 No
DLCO, % predicted 98.8  17.7 91  18.4 No
Radiological stages
0 e 29% e
I e 29% e
II e 22.9% e
III e 16.6% e
IV e 2.08% e
BAL cell count
Macrophages % 88.1  20.5 63  21.3 Yes
Lymphocytes % 7.5  14.04 33.3  20.8 Yes
Neutrophils % 1.1  12.6 1.0  0.3 No
Eosinophils % 0.7  9.1 1.0  1.1 No
CD4/CD8 1.9  1.1 4.9  3.2 Yes
ACE (IU/min/ml) e 52.8  13.3 e
Figure 1 The two isoforms of SAA1 (spot A and spot B) in
a two-dimensional electrophoresis gel of a sarcoidosis patient.
Figure 2 Serum concentrations of SAA (mg/ml) in sarcoidosis
patients and controls (p < 0.01) (ELISA). The box extends from
25th to 75th percentile, with a line at the median (50th
percentile).
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Concentrations of this protein in serum were inversely
correlated with FEV1 percentages in sarcoidosis patients
(rZ0.3; pZ 0.03). No significant correlations were found
betweenSAAconcentrations andFVCpercentages (rZ0.1;
pZ 0.19) or DLCO values (rZ0.2; pZ 0.12) or radiological
stages (r Z 0.1; p Z 0.4) or serum ACE levels (r Z 0.08;
pZ 0.6). Serum concentrations of SAAwere evaluated in the
three SCAC classes (into which our cohort of patients with
subacute onset was differentiated). SAA levels in SCAC
classes 4, 5 and 6 were reported in Fig. 3. Concentrations of
this acute phase protein were significantly higher in the class
of patients requiring prolonged and repeated treatmentwith
steroids (more than 12 months) at onset or during follow-up
(SCAC group 6) than in patients who did not require anyTable 3 Spot A and Spot B percentage volumes (%vol)
analyzed by proteomic approach in serum of seven
sarcoidosis patients with short description of clinical
manifestations.
Spot A Spot B
Patient 1 (minimal
pulmonary sarcoidosis)
e e
Patient 2 (severe
pulmonary and ocular sarcoidosis)
188 209
Patient 3 (minimal pulmonary,
lympho node and cutaneous sarcoidosis)
28 39
Patient 4 (severe pulmonary and
cutaneous sarcoidosis)
77 46
Patient 5 (minimal pulmonary
involvement)
5 3
Patient 6 (pulmonary and spleen
involvement)
24 34
Patient 7 (minimal pulmonary and
lympho node disease)
4 etherapy (SCAC group 4) (p < 0.001) or requiring less than 1
year treatment (SCAC 5; p < 0.05).
Discussion
Serum amyloid A is an acute phase protein involved in
inflammation and lipid metabolism.28,29 In the present study
we identified serum amyloid A1 (the major isotype of SAA) in
sarcoidosis patients by two-dimensional electrophoresis and
quantified its percentage volumes in patients and controls.
SAA1 consisted of two isoforms in gels of sarcoidosis patients
but was not found in gels of healthy controls. Potential
involvement of this protein in the immunoinflammatory
pathogenesis of sarcoidosis was also suggested by evidence
of significantly higher serum concentrations of SAA1 in
sarcoidosis patients than controls detected by ELISA in
a larger population. In our study, serum concentrations of
SAA were inversely correlated with FEV1 values.Figure 3 Serum concentrations of SAA (mg/ml) in our pop-
ulation of patients divided into three groups according to
phenotype activity score (SCAC). Class 4 SCACZ patients with
subacute onset and no need for systemic steroid therapy. Class
5 SCACZ patients with subacute onset requiring one period of
immunosuppressive treatment, lasting 12 months or less. Class
6 SCAC Z patients with subacute onset requiring several
periods of immunosuppressive treatment or protracted treat-
ment (more than 1 yr).
SAA in sarcoidosis 779Increased serum levels of SAA have been reported in
patients with active sarcoidosis (defined as progressive
deterioration of radiological and functional features). In
our study we observed significantly higher concentrations
of this protein in patients requiring prolonged steroid
treatment (more than a year) at onset or during follow-up,
than in patients who did not require immunosuppressive
therapy.19 Salazar suggested a potential role of serum
amyloid A and high-density lipoprotein cholesterol as
biomarkers of sarcoidosis activity.18 More recently, Miyoshi
et al. evaluated serum concentrations of SAA, IL-2
receptor, ACE, lysozyme and KL6 in 43 sarcoidosis patients
at onset, seeking a correlation with lymphocytic alveoli-
tis.30 The study concluded that although serum levels of
SAA may be useful to monitor sarcoidosis activity (espe-
cially in follow-up), they did not reflect BAL alveolar
lymphocytes as well as the biomarkers KL-6, sIL-2r and
lysozyme.30
With regard to the literature, Bons and coworkers
recently applied surface-enhanced laser desorption ioni-
zation time-of-flight mass spectrometry (SELDI-TOF-MS) to
the study of serum from sarcoidosis patients and controls in
an endeavor to identify new protein biomarkers.31 They
reported two unidentified serum proteins that were up-
regulated in sarcoidosis patients. The molecular weights of
these two proteins corresponded to those of the two iso-
forms of SAA1 (spot A and B) identified by us. These authors
showed that the proteins with m/z values of 11,955 and
11,734 were up-regulated in serum of sarcoidosis patients
and had much higher sensitivity and specificity than ACE
and sIL-2R: 86% sensitivity and 63% specificity for the one
with m/z Z 11,955 and sensitivity 74% and specificity 71%
for the one with m/z Z 11,734.31 The correspondence
between the molecular weight of the proteins of Bons et al.
and our isoforms of SAA prompts us to suggest that SAA is
the unidentified biomarker of Bons’s proteomic study, over-
expressed in sarcoidosis and characterized by very high
sensitivity and specificity.31 This observation has particular
relevance because a recent paper reported a crucial
pathogenetic role of SAA in granulomatous inflammation of
sarcoidosis.20 The authors demonstrated that serum
amyloid A is a component of the innate immune response
regulating granulomatous inflammation in sarcoidosis
through Toll-like receptor-2. Th1/Th2 balance and granu-
loma formation in sarcoidosis is influenced by this protein
that could be targeted by new treatments.20
In conclusion, our results suggest that serum amyloid A
could be a useful marker of sarcoidosis, since its serum
concentrations are significantly higher in sarcoidosis patients
than controls (especially patients with reduced FEV1
requiring prolonged and repeated steroid treatment), SAA1
spots are only found in 2-DE gels of sarcoidosis patients and
not in healthy subjects and they couldmatch theunidentified
biomarker of sarcoidosis reported in a previous proteomic
study by another research group.31 A large prospective study
is now needed to verify its clinical utility.
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